Forte Biosciences, Inc.是一家臨床階段的皮膚病學公司,致力於開發用於治療炎症性皮膚病的活體生物療法FB-401。 FB-401已完成對成人和兒童(3歲及以上)特應性皮炎患者的1/2a期測試。 對於安全和有效的療法,特別是對於小兒特應性皮炎患者,存在大量的需求。Forte計劃在2020年代中期將FB-401推進到2期臨床試驗中。
董事
名稱
職位
Faheem Hasnain
Director and Chairman of the Board
Martin J. Duvall
Director and Chief Executive Officer
Harry E. Gruber
Director and President, Science and Innovation
David Parkinson
Director
Franklin M. Berger
Director
Lori Kunkel
Director
Paul Schimmel
Director
Thomas E. Darcy
Director
股東
名稱
職位
Martin J. Duvall
Director and Chief Executive Officer
Asha Das
Senior Vice President and Chief Medical Officer
Mark Foletta
Executive Vice President and Chief Financial Officer
Douglas Jolly
Executive Vice President, Research and Pharmaceutical Development